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OBJECTIVEdTo evaluate the rate and determinants of concordance between advanced di-
abetic retinopathy (DR) and chronic kidney disease (CKD), as assessed by both albuminuria and
estimated glomerular ﬁltration rate (eGFR), in the large cohort of the Renal Insufﬁciency And
Cardiovascular Events (RIACE) Italian multicenter study.
RESEARCH DESIGN AND METHODSdPatients with type 2 diabetes (n = 15,773)
visiting consecutively 19 hospital–based diabetes clinics in years 2007 and 2008 were examined.
DR was assessed by dilated fundoscopy. CKD was deﬁned based on albuminuria and eGFR.
RESULTSdCKDwas present in 58.64% of subjects with advanced DR, whereas advanced DR
was detectable only in 15.28% of individuals with any CKD and correlated with the albuminuric
CKD phenotypes more than with the nonalbuminuric phenotype. Age, male sex, diabetes
duration, hemoglobin A1c, hypertension, triglycerides, previous cardiovascular disease, and,
inversely, HDL-cholesterol correlated independently with the presence of any CKD in individ-
uals with advanced DR; correlates differed according to the presence of albuminuria, reduced
eGFR, or both. Conversely, factors associated with the presence of advanced DR in subjects with
any CKDwere diabetes treatment, previous cardiovascular disease, albuminuria, and, inversely,
smoking, eGFR, and age at diagnosis.
CONCLUSIONSdConcordance of CKD with advanced DR is low in subjects with type 2
diabetes, and CKDwithout advanced DR is more frequent than isolated advanced DR, at variance
with type 1 diabetes. Factors independently associated with the presence of any CKD in indi-
viduals with advanced DR differ, at least in part, from those correlating with the presence of
advanced DR in subjects with any CKD and by CKD phenotype.
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D iabetic retinopathy (DR) and dia-betic nephropathy (DN) are themain microvascular complications
of diabetes, representing the leading
cause of blindness (1) and end-stage renal
disease (2), respectively. Hyperglycemia
is believed to play a central role in the
initiation and progression of both compli-
cations, as shown by their prevention or
retardation by intensive glycemic control
in patients with type 1 and 2 diabetes
(3,4), thus suggesting common pathoge-
netic mechanisms. Accordingly, in type 1
diabetes, DR often is associated with albu-
minuria, and subjects with DN almost al-
ways have DR (5), whereas in type 2
diabetes, the concordance rate between
these two complications seems to be
lower (6), although studies investigating
this association within large samples are
lacking.
Interestingly, in type 2 diabetes, con-
cordance between reduced glomerular
ﬁltration rate (GFR) and albuminuria
also ismuch lower than in type 1 diabetes.
In fact, of patients with type 2 diabetes
from the UK Prospective Diabetes Study,
67% were normoalbuminuric at the time
they developed chronic kidney disease
(CKD), as deﬁned by an estimated GFR
(eGFR) ,60 mL/min/1.73 m2; of these,
51% remained normoalbuminuric,
whereas 16% developed albuminuria
thereafter (7). Conversely, in the Diabetes
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Control and Complications Trial/
Epidemiology of Diabetes Interventions
and Complications study, only 24% of
subjects with type 1 diabetes who devel-
oped CKD were normoalbuminuric (8).
Thus, in type 2 diabetes, CKD often occurs
in the absence of DR or albuminuria, which
is the main criteria for differential diagnosis
between DN and nondiabetic renal disease.
Among subjects with CKD from the
Third National Health and Nutrition Ex-
amination Survey, 30% had neither DR
nor albuminuria and many of them
showed only one of these abnormalities
in addition to reduced eGFR (9). Unfortu-
nately, previous studies of the association
between DN and DR used only albumin-
uria or proteinuria as CKD markers and,
hence, did not consider eGFR, and most
of them did not distinguish advanced
sight-threatening lesions from nonad-
vanced or no DR (6,10–12).
This study aimed to evaluate the rate
and determinants of concordance be-
tween advanced DR with CKD, as evalu-
ated by both albuminuria and eGFR, in
the large cohort of patients with type 2
diabetes from the Renal Insufﬁciency And
Cardiovascular Events (RIACE) Italian
multicenter study.
RESEARCH DESIGN AND
METHODS
Patients
We used the data collected during the
baseline visit for the RIACE Italian mul-
ticenter study (registered with Clinical-
Trials.gov, NCT00715481; URL http://
clinicaltrials.gov/ct2/show/NCT00715481),
an observational, prospective cohort study
of the impact of eGFR on the morbidity
and mortality of cardiovascular disease
(CVD) in subjects with type 2 diabetes.
The RIACE cohort consisted of
15,933 Caucasian patients with type 2
diabetes (deﬁned by the American Di-
abetes Association criteria) presenting
consecutively to 19 hospital-based diabe-
tes clinics of the National Health Service
throughout Italy (see the list of partici-
pating diabetes centers in the Supplemen-
tary Data online) during the years 2007
and 2008. Exclusion criteria were di-
alysis or renal transplantation. The study
protocol was approved by the locally
appointed ethics committees. The quality
and completeness of data were controlled
and 160 patients were excluded because
of missing or implausible values; data
from the remaining 15,773 patients were
subsequently analyzed.
Measurements
All patients underwent a structured in-
terview to collect the following informa-
tion: age; smoking status; known diabetes
onset and duration; and current glucose,
blood pressure (BP), and lipid-lowering
therapies, with indication of the class of
drug. Weight and height were assessed
and BMIwas calculated, then BPwasmea-
sured with a sphygmomanometer after 5
min of rest. Hemoglobin A1c (HbA1c) was
measured with high-performance liquid
chromatography using methods aligned
with those in the Diabetes Control and
Complications Trial; triglycerides and to-
tal and HDL cholesterol were determined
by standard analytical methods; LDL cho-
lesterol was calculated using the Fried-
wald formula.
The presence of DR was assessed by
an expert ophthalmologist using dilated
fundoscopy. Patients were classiﬁed into
the following categories: absent DR; mild,
moderate, or severe nonproliferative DR
(non-PDR); proliferative DR (PDR); or
maculopathy, according to the Global Di-
abetic Retinopathy Project Group (13).
Patients were classiﬁed on the basis of
the actual fundus appearance or the reti-
nal disease condition that had eventually
required previous photocoagulation or
surgical treatment. For further analysis,
patients with a mild (microaneurysms
only) or moderate (microaneurysms and
other microvascular lesions) degree of
non-PDR were classiﬁed as having non-
advanced DR, whereas those with severe
non-PDRor pre-PDR (i.e.,microaneurysms/
hemorrhages in four quadrants, or venous
beadings in two quadrants, or intraretinal
microvascular abnormalities in one quad-
rant); PDR (i.e., neovascularization from
the disc or from elsewhere, vitreous hem-
orrhages, or tractional retinal detach-
ment); maculopathy (retinal thickening
or hard exudates distant from, approach-
ing, or involving the center of the macula);
or blindness (if less than 1/10 normal vi-
sion or 20/200 on the Snellen test) either
were grouped into the advanced, sight-
threatening DR category or were consid-
ered separately as patients with severe
non-PDR or PDR and patients with mac-
ulopathy. Subjects with maculopathy
and nonadvanced DR were classiﬁed as
having maculopathy, whereas those with
maculopathy and severe non-PDR or PDR
were classiﬁed as having one of the latter
conditions. DR grade was assigned based
on the worst eye.
The presence of CKD was assessed
by measuring albuminuria and serum
creatinine. As previously reported in detail
(14), albumin excretion rate (AER) was
obtained from timed (24 h) urine collec-
tions or calculated from the albumin-to-
creatinine ratio (A:C) in early morning,
ﬁrst-voided urine samples in the absence
of symptoms and signs of urinary tract in-
fection or other interfering clinical condi-
tions. Albuminuria was measured in one,
two, or three fresh urine samples for each
patient using immunonephelometry or
immunoturbidimetry and, in cases ofmul-
tiple measurements, the geometric mean
was used for analysis. In subjects with
multiple measurements (4,062 with at
least two and 2,310 with three values),
the concordance rate between the ﬁrst
value and the geometric mean was
.90% for all classes of albuminuria (14).
Patients then were assigned to one of the
following categories of albuminuria (milli-
grams per 24 h): normoalbuminuria (AER
,30), microalbuminuria (AER 30–299),
or macroalbuminuria (AER$300). In ad-
dition, normoalbuminuric subjects were
further classiﬁed as having normal (AER
,10) or low albuminuria (AER,10–29),
according to the recent deﬁnition of the
National Kidney Foundation (15). Serum
(and urine) creatinine wasmeasured using
the modiﬁed Jaffe method. One to three
measurements were obtained for each pa-
tient and eGFR was calculated using the
four-variable equation from the Modiﬁca-
tion of Diet in Renal Disease study (16) or
the equation from the Chronic Kidney
Disease Epidemiology Collaboration
(17), and the mean serum creatinine value
was used in cases of multiple measures, as
reported in previous publications (14,18).
Patients then were assigned to one of the
following categories of eGFR: 1 ($90), 2
(60–89), 3 (30–59), 4 (15–29), and 5 (,15
mL/min/1.73 m2). Finally, subjects were
classiﬁed as having no CKD or CKD
stages 1–5 on the basis of the presence
or absence of micro- or macroalbumin-
uria and the value of eGFR, according to
the National Kidney Foundation’s Kid-
ney Disease Outcomes Quality Initiative
(19). Patients assigned to CKD stages
(and GFR classes) 4 and 5 were pooled
together. As previously reported (18), pa-
tients with CKD were further classiﬁed as
having one of the following CKD pheno-
types: albuminuria alone (CKD stages
1–2), reduced eGFR alone (CKD stage
$3 without albuminuria), or both (CKD
stage$3 with albuminuria).
Prevalent CVD was assessed from the
medical history by recording docu-
mented previous major acute CVD events,
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including myocardial infarction; stroke;
foot ulcer or gangrene; amputation; coro-
nary, carotid, and lower-limb revasculari-
zation; and surgery for aortic aneurysm.
CVD events were adjudicated based on
hospital discharge records or specialist
visits by an ad hoc committee at each
participating center (20).
Statistical analysis
Data are expressed as median (interquar-
tile range) for continuous variables and as
numbers of cases and percentages for
categorical variables. Patients were strat-
iﬁed by DR grade and CKD phenotype,
and prevalence rates were calculated for
each combination.
Logistic regression analyses with step-
wise variable selection were performed to
assess the independent association of CKD
phenotypes with nonadvanced or ad-
vanced DR compared with no DR; ad-
vanced DR was further divided into severe
non-PDR plus PDR and maculopathy. Co-
variates were age, sex, smoking status,
known diabetes duration or age at diabetes
diagnosis,HbA1c,hypertension,dyslipidemia,
triglycerides, HDL cholesterol, and previ-
ousmajor acute CVD events. Hypertension
was deﬁned as systolic BP $140 mmHg,
diastolic BP$90 mmHg, antihypertensive
treatment, or all three. Dyslipidemia was
deﬁned as high LDL cholesterol, lipid-
lowering treatment, or both, whereas high
triglycerides and low HDL cholesterol
were considered separately. Results of these
analyses were expressed as odd ratios
(ORs) with their 95% CIs.
Then, subjects with no or advanced
DR were stratiﬁed by the presence or
absence of DR and CKD, and groups
were compared using the following sta-
tistical tests: one-way ANOVA and the
Kruskall-Wallis test for parametric and
nonparametric continuous variables, re-
spectively, and Pearson x2 for categori-
cal variables.
Further analyses were applied to
identify variables independently associ-
ated with the presence versus absence of
CKD (either any or by phenotype) in
subjects with advanced DR and with the
presence versus absence of advanced DR
in subjects with CKD. Covariates were
risk factors, previous major acute CVD
events, and, in the latter instance, albu-
minuria and eGFR.
All P values were two-sided, and a P
value less than 0.05 was considered sta-
tistically signiﬁcant. Statistical analyses
were performed using SPSS version 13.0
(SPSS Inc., Chicago, IL).
RESULTSdPrevalence rates of CKD
phenotypes according to DR grading are
shown in Table 1. The majority of sub-
jects (8,182; 51.87%) had neither DR
nor CKD, whereas concordance between
DR and CKD was found only in 1,814
individuals (11.50%). Of these subjects,
911 (50.22%) had nonadvanced DR and
903 (49.78%) had advanced DR, whereas
882 patients (48.62%) had stage 1 or 2
CKD, 393 (21.66%) had nonalbuminuric
stage $3 CKD, and 539 (29.72%) had
albuminuric stage$3 CKD, thus indicat-
ing that DR is more frequent in the albu-
minuric than in the nonalbuminuric CKD
phenotypes. Overall, advanced DR was
found in 15.28% of the 5,908 individuals
with any CKD, and CKD was detected in
58.64% of subjects with advanced DR.
Discordance between DR and CKD was
observed in 5,777 subjects (36.63%). Of
these, 1,683 (10.67%) had only DR,
1,046 (62.15%) had nonadvanced DR,
and 637 (37.85%) had advanced DR;
4,094 (25.96%) had only CKD, 2,067
(50.49%) had stage 1 or 2 CKD, 1,280
(31,27%) had nonalbuminuric stage $3
CKD, and 747 (18.25%) had albuminuric
stage $3 CKD. In addition, of the 2,959
patients with reduced eGFR, 1,498
(50.63%) had neither albuminuria nor
advanced DR, whereas, of the 4,235 sub-
jects with albuminuria, 2,509 (59.24%)
had neither reduced eGFR nor advanced
DR, thus indicating that both isolated
reduced eGFR and albuminuria often
occurred without advanced DR (Supple-
mentary Figure 1). The albuminuric CKD
phenotypes without (OR 2.142 [95% CI
1.858–2.468]) and with (OR 2.967
[2.473–3.559]) reduced eGFR, were as-
sociatedmore strongly with advanced DR
than the nonalbuminuric one (OR 1.290
[1.059–1.570]).
Further analyses were conducted in
subjects with no or advanced DR, strati-
ﬁed by presence or absence of any CKD,
thus excluding the 1,957 subjects with
nonadvanced DR (1,046 without and 911
with CKD). The clinical characteristics of
these patients are presented in Table 2.
Subjects with advanced DR, either alone
or associated with CKD, were less fre-
quently smokers and had a younger age
at diabetes diagnosis, longer duration of
diabetes, and higher HbA1c. Patients
with CKD, either alone or associated
with advanced DR, were older and had
higher triglyceride and lower HDL cho-
lesterol levels. Systolic but not diastolic
BP was higher in individuals with ad-
vanced DR, CKD, or both. In the pres-
ence of CKD, albuminuria was much
higher in subjects with than in those with-
out advanced DR, whereas serum creati-
nine and eGFR did not differ between
these two groups. CVD event and treat-
ment rates were higher in subjects with ad-
vanced DR (particularly peripheral events)
or CKD (especially coronary and cerebro-
vascular events and treatments) than in
those without, and the rates increased
markedly when both complications were
present.
Logistic regression analysis carried
out in individuals with advanced DR
(Table 3) showed that factors indepen-
dently associated with any CKD versus
no CKD were age, male sex, HbA1c, dura-
tion of diabetes, combined therapy with
insulin and oral agents, triglycerides, hy-
pertension, previous CVD event, and, in-
versely, HDL cholesterol. Conversely,
smoking status, dyslipidemia, andd
when substituted for age and duration of
diabetesdage at diabetes diagnosis (data
not shown) were excluded from the
model. Moreover, correlates differed ac-
cording to the CKD phenotype: stage 1 or
2 CKD was associated with male sex,
HbA1c, hypertension, and previous
CVD; albuminuric stage$3 CKD was as-
sociated with age, former smoking, dura-
tion of diabetes, hypertension, and
previous CVD; and nonalbuminuric stage
$3 CKD was associated with age and
Table 1dPrevalence of CKD phenotypes according to DR grade
CKD phenotype No DR Nonadvanced DR Advanced DR Total
No CKD 8,182 (51.87) 1,046 (6.63) 637 (4.04) 9,865 (62.54)
Stage 1 or 2 2,067 (13.10) 442 (2.80) 440 (2.79) 2,949 (18.70)
Stages 3–5
Nonalbuminuria 1,280 (8.12) 218 (1.38) 175 (1.11) 1,673 (10.61)
Albuminuria 747 (4.74) 251 (1.59) 288 (1.83) 1,286 (8.16)
Total 12,276 (77.83) 1,957 (12.41) 1,540 (9.76) 15,773 (100)
Data are n (%).
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female sex. Triglycerides correlated with
all three phenotypes (data not shown).
Logistic regression analysis per-
formed for individuals with CKD (Table
4) showed that diabetes treatment (partic-
ularly with insulin, either alone or com-
bined with oral agents), previous CVD,
reduced eGFR, albuminuria, and, in-
versely, age at diabetes diagnosis (or age;
data not shown) and smoking correlated
with presence of advanced DR, whereas
sex, HbA1c, hypertension, and lipid ab-
normalities were excluded from the
model.
Results did not change when subjects
with nonadvanced DR were taken into
consideration and pooled with individuals
with no DR as opposed to those with
advanced DR and when patients with
maculopathy alone were excluded from
the analysis (data not shown).
CONCLUSIONSdThis is the ﬁrst
study investigating the association be-
tween advanced DR and CKD in a large
sample of subjects with type 2 diabetes
with combined assessment of albumin-
uria and eGFR and stratiﬁcation of pa-
tients by CKD phenotype. Main ﬁndings
are that 1) the two complications coexist
in only a small percentage of these pa-
tients; 2) CKD is present in approximately
60% of subjects with advanced DR,
whereas advanced DR is detectable in ap-
proximately 15% of individuals with any
CKD; 3) the albuminuric CKD pheno-
types are stronger correlates of advanced
DR than the nonalbuminuric one; and 4)
factors independently associated with the
presence of any CKD in individuals with
advanced DR differ from those correlated
with presence of advanced DR in subjects
with any CKD and differ according to the
CKD phenotype.
The ﬁnding that only 11.50% of indi-
viduals from the RIACE cohort had both
complications is consistent with previous
reports showing a lower concordance rate
Table 2dClinical characteristics of study subjects with no or advanced DR, stratiﬁed by presence or absence of any CKD*
Variables
No DR or CKD
(n = 8,182)
DR but no CKD
(n = 637)
CKD but no DR
(n = 4,094)
DR and CKD
(n = 903) P†
Age, years 65 (58–71) 66 (59–72) 70 (62–76) 68 (61–74) ,0.0001
Male sex 4,592 (56.1) 344 (54.0) 2,367 (57.8) 526 (58.3) 0.114
Smoking ,0.0001
Never 4,676 (57.1) 400 (62.8) 2,227 (54.4) 524 (58.0)
Former 2,227 (27.2) 150 (23.5) 1,233 (30.1) 270 (29.9)
Current 1,279 (15.6) 87 (13.7) 634 (15.5) 109 (12.1)
Age at diabetes diagnosis, years 54 (46–61) 48 (40–55) 56 (48–64) 48 (39–56) ,0.0001
Duration of diabetes, years 8 (4–15) 17 (10–24) 11 (5–20) 20 (12–27) ,0.0001
HbA1c, % 7.08 (6.40–7.93) 7.70 (6.81–8.78) 7.32 (6.55–8.34) 7.94 (7.00–9.14) ,0.0001
HbA1c, nmol/mL 53.88 (46.45–63.17) 60.66 (50.93–72.46) 56.50 (48.09–67.65) 63.28 (53.01–76.39) ,0.0001
BMI, kg/m2
Men 27.54 (25.06–30.46) 27.38 (25.15–30.01) 28.37 (25.63–31.31) 28.92 (25.95–31.71) ,0.0001
Women 28.72 (25.32–32.64) 29.62 (26.26–33.47) 29.38 (26.06–33.21) 30.28 (26.57–34.82) ,0.0001
Triglycerides, mmol/L 1.28 (0.93–1.78) 1.23 (0.91–1.68) 1.46 (1.07–2.08) 1.51 (1.08–2.12) ,0.0001
Total cholesterol, mmol/L 4.76 (4.16–5.38) 4.58 (4.03–5.26) 4.73 (4.09–5.43) 4.68 (4.03–5.33) ,0.0001
HDL cholesterol, mmol/L
Men 1.19 (1.01–1.42) 1.16 (0.98–1.45) 1.13 (0.96–1.34) 1.14 (0.93–1.34) ,0.0001
Women 1.37 (1.16–1.60) 1.37 (1.17–1.63) 1.29 (1.09–1.55) 1.27 (1.05–1.50) ,0.0001
LDL cholesterol, mmol/L 2.78 (2.26–3.33) 2.65 (2.16–3.16) 2.71 (2.19–3.33) 2.65 (2.11–3.21) ,0.0001
Systolic BP, mmHg 135 (125–148) 140 (130–150) 140 (130–150) 140 (130–155) ,0.0001
Diastolic BP, mmHg 80 (70–85) 80 (70–84) 80 (70–85) 80 (70–80) 0.009
Albuminuria, mg/24 h 9.3 (5.0–15.0) 10.0 (5.5–16.5) 45.1 (18.2–105.3) 82.0 (34.1–269.3) ,0.0001
Serum creatinine, mmol/L 74.26 (63.65–83.98) 75.14 (67.18–84.86) 91.05 (77.79–114.92) 97.24 (79.56–123.76) ,0.0001
eGFR MDRD, mL/min/1.73 m2 84.0 (73.5–97.0) 80.7 (71.7–94.0) 60.6 (51.1–83.7) 59.1 (46.2–80.6) ,0.0001
eGFR CKD-EPI, mL/min/1.73 m2 89.3 (78.1–98.2) 87.9 (76.2–96.2) 63.5 (50.8–88.3) 61.5 (46.1–86.0) ,0.0001
Any CVD event 1,317 (16.1) 172 (27.0) 1,177 (28.7) 366 (40.5) ,0.0001
AMI 661 (8.1) 88 (13.8) 568 (13.9) 154 (17.1) ,0.0001
Stroke 170 (2.1) 20 (3.1) 183 (4.5) 62 (6.9) ,0.0001
Foot ulcer/gangrene 106 (1.3) 39 (6.1) 144 (3.5) 124 (13.7) ,0.0001
Coronary revascularization 604 (7.4) 74 (11.6) 509 (12.4) 132 (14.6) ,0.0001
Carotid revascularization 280 (3.4) 21 (3.3) 285 (7.0) 77 (8.5) ,0.0001
Lower limb revascularization 118 (1.4) 24 (3.8) 137 (3.3) 73 (8.1) ,0.0001
Lipid-lowering treatment 3,526 (43.1) 296 (46.5) 2,022 (49.4) 493 (54.6) ,0.0001
Antihypertensive treatment 5,063 (61.9) 447 (70.2) 3,345 (81.7) 782 (86.6) ,0.0001
ACE inhibitor/ARB treatment 4,002 (48.9) 382 (60.0) 2,768 (67.6) 701 (77.6) ,0.0001
Data are median (interquartile range) or n (%). *The 1,957 subjects with nonadvanced DR (1,046 without and 911 with CKD) were excluded from the analysis †One-
way ANOVA and Kruskall-Wallis test for parametric and nonparametric continuous variables (triglycerides, albuminuria, serum creatinine, eGFR based on the
Modiﬁcation of Diet in Renal Disease study [MDRD], eGFR based on the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]); Pearson x2 for categorical
variables. AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker.
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in type 2 than in type 1 diabetes (5,6). The
percentage of subjects with advanced DR
showing any CKD (64%) is lower in type
2 diabetes than that observed in type 1 di-
abetes (5) but similar to that reported by
Gall et al. (6) and Magri et al. (11) in type 2
diabetes, thus conﬁrming that DR is a risk
factors for DN in these individuals (8).
Moreover, themajority of subjects with ad-
vanced DR and CKD had increased albu-
minuria with or without reduced eGFR,
which is in keeping with the observation
that DR is a risk factor for albuminuria
but not for lower eGFR in individuals
with type 2 diabetes (8). On the contrary,
the prevalence of advanced DR in patients
with CKD was quite low (15.28%) in our
study, indicating that concordance be-
tween advanced DR and CKD is different
in type 2 diabetes compared with type 1
diabetes. In fact, the ﬁnding that detection
of any or advanced DR in subjects with
CKD was less frequent than the presence
of CKD in subjects with any or advanced
DR is at odds with the observation that, in
type 1 diabetes, DR occurs almost invari-
ably in individuals with CKD, whereas the
latter does not always develop in patients
with DR (5). This ﬁnding is also in contrast
with the report that, in subjects with type 2
diabetes, DR was present in the majority of
those with DN and in none or few of those
without DN based on renal biopsy (21,22)
and, hence, with the concept that DR
represents a major criterion for the diagno-
sis ofDN. The reason for this discrepancy is
that considering CKD (i.e., increased albu-
minuria, reduced eGFR, or both) instead of
albuminuria alone as a marker of DN im-
plies the inclusion of individuals with non-
albuminuric CKD (i.e., reduced eGFR
alone), an increasingly frequent clinical
phenotype of CKD that shows a weak re-
lationship with DR.
A growing body of evidence indicates
that this CKD phenotype has become the
predominant form of renal impairment
(i.e., eGFR,60 mL/min/1.73 m2) in sub-
jects with type 2 diabetes (8,18,23), at
variance with type 1 diabetes (7). In the
RIACE cohort, the prevalence of the non-
albuminuric form was 56.6%, and this
phenotype correlated with any or ad-
vanced DR less strongly than the albu-
minuric phenotypes (18) and vice versa.
In addition, DR is a risk factor for albu-
minuria but not for reduced eGFR (8),
and a recent prospective study showed
that albuminuria with nonreduced
eGFR is a stronger predictor of DR than
reduced eGFR without albuminuria in
subjects with type 2 diabetes (24). These
ﬁndings, together with the lack of asso-
ciation of nonalbuminuric renal im-
pairment with HbA1c, prompted the
hypothesis that macroangiopathy, rather
than microangiopathy, is the predomi-
nant underlying renal pathology in sub-
jects with nonalbuminuric CKD (18),
which might explain, at least in part, the
low concordance rate between advanced
DR and CKD (particularly the nonalbu-
minuric phenotype) in individuals with
type 2 diabetes. This explanation is con-
sistent with the more marked anatomical
heterogeneity of DN in type 2 than type 1
diabetes. In fact, although typical diabetic
glomerulopathy almost invariably under-
lies DN in subjects with type 1 diabetes
(25), it can be detected in only one third
of patients with type 2 diabetes and mi-
croalbuminuria; the remaining two thirds
show prevailing vascular and/or tubuloin-
terstitial injury or no signiﬁcant lesions
(26). The increasing use of blockers of the
renin-angiotensin system (RAS) also has
been claimed to explain the weaker associ-
ation of the nonalbuminuric CKD pheno-
type with DR (18,24). In recent large trials,
these agents were shown to be effective in
preventing renal disease in individuals with
diabetes and DR (27). The antiproteinuric
effect of RAS blockers might contribute to
protection beyond the reduction of BP
levels, not only from DN (28) and CVD
(29), but also from DR, as suggested by the
strong correlation between this complica-
tion and albuminuria. However, the per-
centage of subjects with the albuminuric
phenotype who were taking RAS blockers
was higher than that of patients with the
nonalbuminuric phenotype, though this
might simply be an indication effect (18).
An intriguing ﬁnding of this study is
that variables independently associated
with the presence of any CKD in individ-
uals with advanced DR (i.e., age, male sex,
duration of diabetes, HbA1c, hyperten-
sion, high triglycerides, and low HDL
cholesterol) differed from those correlat-
ing with the presence of advanced DR in
subjects with any CKD (i.e., diabetes
treatment, particularly with insulin alone
or combined with oral agents; micro-/
macroalbuminuria more than reduced
eGFR, and, inversely, age/age at diabetes
diagnosis and smoking), thus suggesting
that different risk factors are involved in
these two complications. Interestingly,
classic risk factors correlated with CKD,
whereas DR was predicted by insulin
treatment, which likely is a marker of
worst control or most complicated dis-
ease, and albuminuria more than eGFR,
which is in keeping with the different re-
lation of these two markers of CKD with
DR. DR correlated inversely with age/age
at diabetes diagnosis. Only previous CVD
event(s) correlated independently with
both advanced DR and CKD, suggesting
that CVD risk associated with DR is not
driven entirely by CVD risk factors and
the presence of DN or CKD. Our study
also showed that factors independently
associated with the presence of CKD in
individuals with advanced DR differed ac-
cording to the CKD phenotype, in keep-
ing with previous reports from the RIACE
and other cohorts of subjects with type 2
diabetes, showing that nonalbuminuric
renal impairment is characterized by dis-
tinct clinical features compared with the
albuminuric forms, and particularly by
the association with female instead of
male sex and no or weaker correlation
with HbA1c and hypertension (8,18,30).
Strengths of this study include the
large size of the cohort, the completeness
of data, and the analysis of a contempo-
rary dataset. Limitations include the lack
of data on visual acuity and, in particular,
the use of fundoscopy instead of the
reference method for DR diagnosis, that
is, multiﬁeld stereoscopic retinal photog-
raphy. However, fundus examination by
an ophthalmologist is the most used
method for DR screening and diagnosis
in Italy, whereas fundus photography is
Table 3dLogistic regression analysis with
stepwise variable selection of independent
correlates of any CKD vs. no CKD in
subjects with advanced DR
Variables* Any CKD
Age, years 1.037 (1.024–1.051)
Female sex 0.737 (0.585–0.929)
Duration of
diabetes, years 1.014 (1.002–1.025)
HbA1c, nmol/mL 1.077 (1.006–1.152)
Diabetes treatment
Diet 1.0
OHA 1.292 (0.673–2.482)
Insulin plus OHA 2.069 (1.065–4.021)
Insulin 1.209 (0.617–2.371)
Triglycerides
(30.113 mmol/L) 1.052 (1.034–1.070)
HDL cholesterol
(30.057 mmol/L) 0.938 (0.897–0.980)
Hypertension 1.632 (1.131–2.356)
Previous CVD event 1.458 (1.152–1.846)
Data are OR (95% CIs). *Variables excluded:
smoking, dyslipidemia. OHA, oral hypoglycemic
agents.
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rarely used because of the lack of trained
and qualiﬁed personnel and the abun-
dance of ophthalmologists. On the other
hand, the use of fundoscopy instead of
fundus photography did not allow cen-
tralized evaluation of DR and, hence,
another potential limitation of the study
was assessment by different ophthalmol-
ogists, although they were asked to
complete a standardized report format
for classifying the RIACE participants. To
reduce potential errors due to the lower
sensitivity of fundoscopy and noncentral-
ized fundus evaluation, the analysis of
concordance between DR and CKD con-
sidered only individuals with advanced
DR. Finally, potential limitations con-
cerning the assessment of DN have been
addressed in previous RIACE reports
(14,18,20).
In conclusion, the data from this large
cohort of subjects with type 2 diabetes
show that 1) the concordance rate between
advanced DR and CKD is low and 2) CKD
without advanced DR is more frequent
than isolated advanced DR because of
the weaker association with reduced
eGFR, which often occurs in the absence
of albuminuria and is at variance with type
1 diabetes. Moreover, factors indepen-
dently associated with the presence of
any CKD in individuals with advanced
DR differ, at least in part, from those that
correlate with the presence of advanced
DR in subjects with any CKD and accord-
ing to the clinical CKD phenotype.
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